Last reviewed · How we verify
Syprine (TRIENTINE)
At a glance
| Generic name | TRIENTINE |
|---|---|
| Sponsor | Bausch Health |
| Drug class | Copper Chelator |
| Target | Carbonic anhydrase 14 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Wilson's Disease
Common side effects
- hypochromic microcytic anemia
- rhabdomyolysis
- muscle pain
- weakness
- cramps
- anorexia
- malaise
- melena
- abdominal pain
- aphthoid ulcers
- acute gastritis
- heartburn
Key clinical trials
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. (PHASE3)
- Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
- Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride (PHASE2)
- Real World Evidence Study in Subjects With Wilson's Disease
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy (PHASE2)
- Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). (PHASE1)
- International Wilson's Disease Patient Registry (iWilson Registry)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |